Colon cancer patients with very high vitamin B12 blood levels survived a median of roughly five years. Those with normal levels survived nearly eleven. That gap – identified in a 2026 analysis published in Cancer Research Communications covering more than 37,000 patients across 108 healthcare systems – is striking on its own. Separate research suggests that people with unusually low B12 intake also face a higher cancer risk. The vitamin that billions of people supplement almost reflexively appears, under the right circumstances, at both ends of a cancer risk curve.
Most researchers now suspect the more pressing question is not whether B12 causes cancer, but whether cancer causes B12 levels to shift – and whether an unexpected reading on a routine blood panel is quietly pointing to something clinicians should investigate more urgently.
What vitamin B12 does – and why its role in cell replication matters
Vitamin B12 (cobalamin) is essential for building DNA and maintaining the myelin sheath that protects nerves. It also supports red blood cell maturation and participates in fat and amino acid metabolism, keeping chemical pathways running that the body depends on continuously.
Animal-derived foods are the primary dietary sources of vitamin B12 – meat, fish, dairy, and eggs. Plant-based diets increase the risk of B12 deficiency due to limited intake of animal-source foods, which is why people eating exclusively plant-based diets are routinely advised to supplement.
B12’s central role in DNA replication is where the vitamin B12 cancer connection first emerged. The logic was intuitive: if the body can’t properly repair or copy DNA because it’s short on a key building block, mutations accumulate, and mutated cells can eventually become cancerous. Researchers set out to confirm that picture. What they found was considerably more complicated.
The colon cancer study that shifted the conversation
A globally federated multi-institutional database identified colon cancer patients who had at least one B12 measurement within one year of diagnosis. Researchers stratified patients into three groups: low (below 300 pg/mL), normal (300 – 1,000 pg/mL), and elevated (above 1,000 pg/mL). The dataset, drawn from 108 healthcare systems, included 37,106 patients – large enough to draw meaningful conclusions.
Patients with elevated B12 had a median overall survival of 59.4 months. Those with normal levels survived a median of 129.8 months, and those with low levels survived a median of 137.3 months. In plain terms: patients whose B12 was above 1,000 pg/mL at diagnosis lived an average of roughly five years, versus nearly eleven years for those in the normal range.
Patients with elevated B12 had higher metastatic involvement and tumor stage at diagnosis. They were also more likely to develop new metastases within a year, particularly in the liver. Even after accounting for age, treatment, and other health conditions, patients with high B12 were roughly twice as likely to die as those with low levels.
What the gene expression data added
The same research team analyzed tumor tissue directly, examining gene activity in 283 colon cancer samples from The Cancer Genome Atlas alongside 304 normal colon tissue samples for comparison. Expression of the B12-dependent gene MTR – which builds methionine synthase, an enzyme that requires B12 to construct a DNA building block – was elevated in colon cancer tissue, and increased MTR expression correlated with decreased survival.
Elevated MTR expression was one of only two genes within the folate and methionine cycles that correlated with worsened overall survival in colon cancer patients. Tumors that ran this gene at high activity – potentially to fuel faster cell copying – tracked with the worst outcomes. This identifies a plausible molecular mechanism but does not prove that B12 fuels tumor growth.
Why cancer can alter B12 readings
The most important interpretive shift in recent research is the recognition that elevated B12 on a blood test doesn’t necessarily mean the person consumed or absorbed too much. The reading reflects what’s circulating in the blood – and cancer can drive that number up through its own disruptions, independent of diet.
The liver stores a substantial reserve of B12. When tumors compromise liver function or when cancers spread aggressively to the liver, that stored supply can flood into the bloodstream. The reading on a blood test then reflects an internal redistribution, not excess intake.
Some tumors also ramp up production of haptocorrin, a protein that binds to B12 and carries it through the blood. When tumors increase production of these carrier proteins, more B12 gets bound and kept in circulation – artificially inflating the serum reading without reflecting functional availability.
A 2025 review published in Nutrients noted that incidental findings of high vitamin B12 should always be followed by additional investigation. A persistently elevated B12 with no clear dietary or supplementation explanation warrants further workup, not reassurance.
The American Cancer Society has noted that researchers have reported high vitamin B12 levels in some people with cancer, including blood, stomach, lung, pancreatic, and colorectal cancers – underscoring that this finding is not confined to one disease site.
When low B12 also raises concern
The research on elevated B12 dominates recent headlines, but the deficiency side carries its own weight. Excess cancer risk associated with low B12 intake has been observed among esophageal, lung, and breast cancer patients.
That finding came from a 2024 hospital-based case-control study published in Nutrition and Cancer. A U-shaped association between vitamin B12 intake and cancer risk was observed, with both the lowest and highest intake groups showing elevated risk compared to people in the middle range. The study comprised 3,758 cancer cases and 2,995 controls in Vietnam.
Several important caveats apply. The study relied on food frequency questionnaires – participants had to recall their own eating habits, which introduces error. It was also observational, meaning it can identify associations but cannot establish that B12 intake caused the cancer outcomes observed. Even the “high intake” group in this study consumed an average of roughly 2.97 micrograms of B12 per day, only modestly above the standard recommended intake of 2.4 to 2.8 micrograms for adults.
When B12 is inadequate, DNA replication becomes error-prone. Cells replicate anyway – they have to – but with more copying mistakes. Over years and decades, those errors can accumulate into the kind of genetic damage that drives cancer development.
For a deeper look at how B12 deficiency manifests in the body before cancer is ever a consideration, the warning signs of B12 deficiency are worth understanding – particularly for anyone on a restricted diet or over the age of 50, when absorption naturally declines.
The supplementation question
A separate thread of concern surrounds high-dose B12 supplementation, particularly in men who smoke. The 2017 Vitamins and Lifestyle (VITAL) cohort study, published in the Journal of Clinical Oncology, examined more than 77,000 people aged 50 to 76 and tracked supplement use over a decade. High dosages of vitamin B6 or B12 supplements were associated with three to four times the lung cancer risk in male smokers compared with smokers who did not take the supplements. The doses involved were substantially above normal recommendations: 55 micrograms or more of B12 per day, compared to the standard 2.4 micrograms.
This association did not appear in women, and it did not appear in never-smokers, suggesting that smoking creates a biological environment in which excessive B12 supplementation may add further risk, rather than B12 being inherently carcinogenic on its own.
Some observational research has also suggested a slight increase in lung cancer risk linked to long-term, high-dose B6 and B12 supplementation, particularly among men and smokers, although observational data tracks associations, not causes. Overall, studies of high-dose B vitamin supplements taken over long periods have not shown clear protective effects against cancer incidence or cancer deaths.
B12 from a normal diet containing meat, fish, eggs, dairy, or fortified foods is not usually the issue: it is very difficult to consume too much B12 from food alone. The concerns about excess primarily pertain to supplements taken in doses far exceeding nutritional guidelines.
The causality problem – and why it matters
The studies that find high B12 in cancer patients cannot, by their design, determine whether B12 was elevated before the cancer developed or whether the cancer caused B12 to rise. This reverse causality problem sits at the center of the scientific debate.
A 2022 scoping review published in Nutrients concluded that high B12 in cancer patients is often an “epiphenomenon” – appearing alongside the disease without necessarily triggering it. A 2024 systematic review in Cancer Investigation reached essentially the same conclusion: cancer appears to be doing something to B12 metabolism, not the other way around.
The pattern of elevated B12 correlating with more advanced disease at diagnosis is consistent with this interpretation. More aggressive, more disseminated cancers do more damage to the liver and produce more carrier proteins, which pushes B12 readings higher. The B12 level reflects disease severity rather than causing it.
A 2026 case-control study published in the International Journal of Breast Cancer, conducted across Jordanian hospitals, reinforced this picture. The authors concluded that elevated B12 could serve as a biomarker of cancer – a signal to investigate rather than a driver to target.
Moving forward with B12
For the vast majority of people – especially older adults, vegans, vegetarians, and anyone with absorption issues – maintaining adequate B12 levels remains important for neurological health, blood cell production, and DNA integrity. Deficiency carries its own documented risks and should not be manufactured in the name of cancer prevention.
An unexplained, persistently elevated B12 reading – one that can’t be accounted for by supplementation or recent dietary changes – should prompt clinical follow-up. The liver disruption and tumor carrier-protein mechanisms are well-documented enough that a high B12 result in the absence of an obvious cause warrants investigation for underlying disease, particularly in people with other risk factors.
For people who take B12 supplements, the data on high-dose supplementation in male smokers is a signal worth discussing with a physician. The doses implicated in the VITAL cohort findings were more than 20 times the recommended daily intake, and the risk appeared to interact specifically with smoking. Standard multivitamin doses or low-dose B12 supplements in nonsmokers do not carry the same evidence of concern.
A nutrient found in high quantities among sick patients is not necessarily making them sick. Cancer rewires metabolism, disrupts storage organs, and hijacks transport proteins. B12 levels in cancer patients may say something important about disease progression and severity – and that is exactly how clinicians and researchers are now beginning to use them.
Disclaimer: The author is not a licensed medical professional. The information provided is for general informational and educational purposes only and is based on research from publicly available, reputable sources. It is not intended to constitute, and should not be relied upon as, medical advice, diagnosis, or treatment. Always consult a licensed physician or other qualified healthcare provider regarding any medical condition, symptoms, or medications. Do not disregard, avoid, or delay seeking professional medical advice or treatment because of information contained herein.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: Signs Of Vitamin B12 Deficiency You Should Never Ignore